Registry For Patients Treated With BeneFix In Usual Care Setting In Germany

Pfizer

Status: Completed

Conditions: Hemophilia B

Treatments: Drug: BeneFIX

Study type: Observational

Funder types: Industry

Identifiers

NCT00714415

B1821011 (Other Identifier)

3090A1-4406

Details and patient eligibility

About

The purpose of this observational study is to describe the incidence of adverse events among patients treated with BeneFix® in usual health care settings in Germany.

Full description

Non-interventional study: subjects to be selected according to the usual clinical practice of their physician

Enrollment: 80 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with hemophilia B already receiving or starting treatment with reformulated BeneFIX®.

Exclusion criteria

• Patients with hemophilia B treated with a product other than BeneFIX®.
• Inclusion in the ongoing prospective registry of European hemophilia B patients using BeneFIX®.

Trial design

80 participants in 1 patient group

A

Description:

Patients with Hemophilia B

Treatment:

Drug: BeneFIX